Developer docs
API playgroundTry for free, no card

Search company profiles

ActX

Full company profile

uuid0002irm

Namestring
ActX
Legal namestring
ActX, Inc.
Websiteurl
actx.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

ActX, Inc. is a Seattle-based, privately-held precision medicine company founded in 2012 by Dr. Andrew Ury that operates a cloud-based genomic decision support platform called GenoACT, natively integrated into Electronic Health Record systems via SMART on FHIR standards. The platform processes saliva-collected genetic samples through a CLIA-certified, CAP-accredited laboratory, covering 600,000 genetic variants and 230+ carrier conditions, then automatically checks prescriptions against patient genetics for adverse reactions, efficacy, and dosing, while surfacing actionable hereditary risks within the clinician's existing EHR workflow. An evidence-based KnowledgeBase — curated by clinicians, geneticists, genetic counselors, and clinical pharmacists and continuously updated as new research emerges — powers the underlying clinical logic.

ActX generates revenue through multiple streams: direct-to-patient genetic testing paid out-of-pocket (with HSA/FSA eligibility, not insurance-covered), a $95 medical interpretation service for existing 23andMe customers, quote-based enterprise subscription licensing to health systems and physician practices, and laboratory reporting services sold to other clinical laboratories. Distribution is hybrid, combining direct enterprise field sales, EHR partner marketplaces (Epic App Orchard, athenahealth Marketplace, Oracle Cloud Marketplace, Greenway Marketplace, etc.), and direct-to-consumer sign-up with physician authorization. The company has accumulated 15+ named health system customers including NorthShore, Yale New Haven Health, Baptist Health, Nemours, Cone Health, Mount Sinai, Vancouver Clinic, Lakeland Regional Health, Nicklaus Children's, UAB Medicine, Ochsner, and St. Elizabeth, with integrations spanning 10+ major EHR platforms and an addressable footprint of 75,000+ providers via athenahealth and 100+ EHR systems via NewCrop.

The company is venture-backed only at the angel/early-stage scale (Alliance of Angels, Keiretsu Forum/Capital, Puget Sound Venture Club), with approximately $6.1 million total disclosed funding raised through a December 2022 SEC Form D filing, and an 11-50 employee headcount. It holds CAP laboratory accreditation (passed 2024 inspection with zero deficiencies), CLIA certification, HIPAA compliance, and TX-RAMP Level 2 certification, and has extended multi-year enterprise commitments (e.g., Baptist Health through 2028) and entered a CMS-funded dementia care program (GUIDE Initiative) in 2026.

Short descriptiontext

ActX, founded in 2012, provides EHR-integrated genomic decision support through its GenoACT platform. The system automatically checks prescriptions against patient genetics and identifies actionable hereditary risks for health systems, practices, and patients across 10+ major EHR platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic decision support, pharmacogenomics platform, precision medicine software, EHR-integrated genomics, clinical decision support
Industry2 codes
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Genomics Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Direct Patient Genetic Testing
TypeOne Time License
Description

Patients pay directly for the ActX service after physician authorization. Service includes pharmacogenomics, hereditary risk assessment, and carrier status screening. Currently not covered by insurance. HSA/FSA funds accepted.

actx.com
223andMe Analysis Service
TypeOne Time License
Description

Interpretation service for 23andMe raw genetic data. Patients pay $95 for ActX analysis that provides more extensive coverage on medications, risks, and carrier conditions than standard 23andMe reports.

actx.com
3Health System Enterprise Licensing
TypeSubscription Recurring
Description

Health systems pay for enterprise-wide genomic decision support deployment. Includes EHR integration, provider access, and system-wide analytics. Implementation in weeks rather than years.

actx.com
4Laboratory Reporting Services
TypeSubscription Recurring
Description

Pharmacogenomic reporting services for other laboratories. Includes PDF PGX reports with customizable panels, CAP accredited genomic interpretation, and provider/patient portal options.

actx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
123andMe Analysis - One-time interpretation service
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$95 for ActX analysis of 23andMe raw genetic data. Includes prescription review, risk & risk factors, and carrier status. More extensive coverage than standard 23andMe Health + Ancestry reports.

actx.com
2Full Service - Complete genomic screening
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Complete service including pharmacogenomics, hereditary risk assessment, and carrier status. Paid directly by patients. Price comparable to testing of one or couple of genes.

actx.com
3Pharmacogenomics Service - Medication-focused only
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Focuses on drug-genome interactions and risks affecting medications only. For patients who prefer not to know about hereditary risks. Option to expand to Full Service later for small fee.

actx.com
4Enterprise Health System Deployment
ModelSubscriptionBilling cadenceAnnual
Notes

System-wide implementation for health systems. Customizable content and workflow integration. Pricing not publicly disclosed - quote-based.

actx.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 3 records shown
1GenoACT
Description

ActX's Genetic Clinical Decision Support Service that provides actionable genomic decision support within EHR workflow

actx.com
+2 more records
Core offering1 text field

ActX builds and operates GenoACT, an EHR-integrated genomic decision support platform that automatically checks prescriptions against patient genetics for drug-genome interactions, adverse reactions, efficacy, and dosing, while alerting physicians to actionable hereditary risks and carrier status. The company processes patient saliva samples through its CLIA-certified laboratory using micro-array testing covering 600,000 genetic variants, with continuously updated clinical interpretation delivered in real time inside the physician's existing EHR workflow.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 89-99% of patients carry variants affecting medications
+4 more records
Product overview1 text field

ActX offers a unified genomic decision support platform called GenoACT that provides precision medicine capabilities integrated into Electronic Health Records. The core product portfolio includes the GenoACT Genomic Decision Support platform, ActX Full Service (comprehensive pharmacogenomics, hereditary risks, carrier status), and ActX Pharmacogenomic Service (drug-genome interactions only). Supporting modules include a patient mobile app (My ActX Genomic Profile), Analytics Dashboard for population health insights, Laboratory Reporting services, Medications by Class visualization, Patient Genetic Testing Recommendations, Dosage and Route-Aware Clinical Alerting, and a Traits feature for non-medical genetic information. ActX also offers a 23andMe integration service for interpreting raw genetic data. The platform integrates with 10 major EHR systems including Epic, Oracle Health, Veradigm, and others via SMART on FHIR standards.

Product and service6 records
1GenoACT Genomic Decision Support
CategoryClinical Genomics Software Platform
Description

Core genomic decision support platform integrated into major EHR systems (Epic, Oracle Health, athenahealth, eClinicalWorks, Greenway, NextGen, Veradigm, Aprima, CompuGroup Medical, NewCrop) that automatically checks prescriptions against patient genetics for drug-genome interactions, adverse reactions, efficacy, and dosing, while alerting physicians to actionable hereditary risks and carrier status. Targeted at health systems, hospitals, and physician practices.

2ActX Full Service
CategoryConsumer Genetic Testing Service
Description

Comprehensive genomic screening service for individual patients covering pharmacogenomics (drug-genome interactions), hereditary risk assessment for actionable conditions, and carrier status screening for 230+ genetic diseases. Patients pay directly after physician authorization, with HSA/FSA eligibility.

3ActX Pharmacogenomic Service (PGx-only)
CategoryConsumer Genetic Testing Service
Description

Focused service providing only drug-genome interaction information and medication-related risks for patients who prefer not to receive non-medication hereditary risk information. Upgradeable to Full Service for a small fee.

4My ActX Genomic Profile Mobile App
CategoryPatient Mobile Application
Description

Free mobile application available on iOS and Android that allows patients to access their ActX Genomic Profile, check medications via Med Check functionality, view hereditary risks, and share results with healthcare providers.

5ActX Laboratory Reporting Service
CategoryLaboratory Services
Description

Pharmacogenomic reporting and interpretation service for clinical laboratories, offering PDF PGX reports with customizable panels, discrete genetic data file transmission (CSV/VCF), optional provider/patient portals, CAP-accredited genomic interpretation, and EHR integration capabilities for the lab's customers.

6ActX for 23andMe
CategoryConsumer Genetic Interpretation Service
Description

Medical genetic interpretation service for existing 23andMe customers, providing $95 analysis of raw 23andMe genetic data with more extensive coverage on medications, hereditary risks, and carrier conditions than standard 23andMe Health + Ancestry reports. The interpretation integrates into the patient's medical chart for physician use.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2017-04-11
Description

Aprima Medical Software integration partnership to bring precision medicine into the physician's office. ActX provides genomic decision support integrated with Aprima EHR.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-01-04
Description

ActX partnered with CompuGroup Medical US to integrate real-time genomic decision support into CGM's EHR solutions (CGM webEHR and CGM CLINICAL). CGM Genomics powered by ActX branding. Provides prescription checking and actionable risk alerts within CGM EHR workflow.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-10-13
Description

ActX partnered through athenahealth's 'More Disruption Please' (MDP) program, making ActX part of the athenahealth Marketplace offerings. Links athenaClinicals with ActX capabilities to incorporate genomic decision support into existing physician workflow. Access to athenahealth's network of 75,000+ healthcare providers.

Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2014-10-15
Description

ActX joined Greenway Health online Marketplace as approved partner for PrimeSUITE EHR users. Certified Greenway Marketplace partner. Integration checks prescriptions against patient genetics within Greenway electronic chart.

Strategic tierCoreTypeTechnology or Integration
Description

ActX provides genomic decision support integrated into EpicCare EHR. Available through Epic App Orchard marketplace. ActX is integrated into Order Entry and Genomic tab, checking medications and alerting for actionable risks. Featured Epic customers include NorthShore, Yale New Haven Health, Baptist Health, and others. Epic President Carl Dvorak publicly endorsed ActX's integration capabilities.

6Oracle Health (Cerner)
Strategic tierCoreTypeTechnology or Integration
Description

ActX offers genomic decision support platform built for Oracle Health (Cerner EHR). Available as SMART on FHIR app through Oracle Cloud Marketplace. ActX is a validated Cerner Code developer partner. Provides real-time decision support, alerts for actionable genomic risks, integrated patient Genomic Profile, and customizable content.

actx.com
Strategic tierSecondaryTypeTechnology or Integration
Description

ActX integrated with eClinicalWorks EHR to bring precision medicine to patient care. Turn-key approach focusing on Actionable Genomics checking prescriptions for adverse reactions, efficacy, and dosing. Genomic Profiles accessible within eClinicalWorks patient chart.

Strategic tierSecondaryTypeTechnology or Integration
Description

ActX partnered with NextGen to make genomic decision support available within NextGen EHR workflow. Identifies actionable hereditary risks and alerts clinicians in their inbox for 3-4% of patients with actionable risks.

9NewCrop
Strategic tierCoreTypeTechnology or Integration
Description

ActX partnered with NewCrop prescribing system and associated EHR partners. Integration means providers using 100+ partner EHR systems can see genetically-based alerts about medication efficacy, dosing, and adverse reactions. Access through NewCrop's extensive partner network.

actx.com
Strategic tierSecondaryTypeTechnology or Integration
Description

ActX integrated with Veradigm EHR (formerly Allscripts) and Alterra TouchWorks. Brings Actionable Genomics into practices integrated into the electronic chart. Checks prescriptions and alerts for adverse effects, efficacy, dosing issues.

11NavRx
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration between ActX and NavRx for the GUIDE Dementia Care Initiative. ActX provides dynamic pharmacogenomics reporting for thousands of early dementia patients. Project incorporates pharmacogenomics and metabolomics for medication management, enabled by clinical pharmacists.

actx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pharmacogenomics testing and clinical decision support company offering GeneSight, a PGx panel integrated into mental-health prescribing workflows. Directly comparable to ActX as a PGx-CDS provider targeting clinicians for medication optimization.

TypeDirect peer
Description

Pharmacogenomics decision support platform providing drug-gene interaction alerts for prescribers, with EHR integration. Closely aligned with ActX's GenoACT value proposition of real-time PGx guidance within the prescribing workflow.

TypeDirect peer
Description

PGx knowledge base and clinical decision support vendor that delivers pharmacogenomic interpretation to health systems and labs via APIs and EHR integrations. Comparable to ActX as a content + integration PGx-CDS competitor.

TypeDirect peer
Description

Genomics clinical decision support platform originally built inside Allscripts, delivering precision-medicine insights inside the EHR. Direct functional competitor to ActX, particularly in the Veradigm/Allscripts ecosystem.

TypeDirect peer
Description

Clinical genomics decision support company providing treatment-guidance analytics based on molecular and genetic data. Comparable to ActX as an enterprise clinical genomics decision-support vendor for health systems.

TypeBroad incumbent
Description

Genomics analytics platform for hospitals and labs offering AI-driven interpretation across multiple testing areas. Broader-scope incumbent with overlapping clinical-decision-support capabilities for genomics, though more lab-oriented than EHR-prescribing-focused.

TypeDirect peer
Description

Pharmacogenomics and precision medicine company offering enterprise PGx decision support for health systems and employee benefits. Comparable to ActX in serving large populations with PGx-CDS offerings.

TypeBroad incumbent
Description

Large established genetics testing company with pharmacogenomics (GeneSight) and hereditary risk products. Broader incumbent offering overlap with ActX's PGx and hereditary-risk service lines, though via lab testing rather than primarily EHR-native CDS.

TypeOthers
Description

Consumer genetic testing company whose raw-data files are interpreted by ActX's $95 service. Adjacent partner rather than direct competitor — ActX monetizes 23andMe's installed base by providing medical-grade interpretation.

TypeBroad incumbent
Description

Dominant EHR vendor whose platform is the primary distribution channel for ActX. Represents both the largest go-to-market opportunity and the principal incumbent risk if Epic ships native genomics decision support to compete directly.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration10 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ActX

Clinical Genomics Softwareactx.com

ActX, founded in 2012, provides EHR-integrated genomic decision support through its GenoACT platform. The system automatically checks prescriptions against patient genetics and identifies actionable hereditary risks for health systems, practices, and patients across 10+ major EHR platforms.

What ActX does

ActX, Inc. is a Seattle-based, privately-held precision medicine company founded in 2012 by Dr. Andrew Ury that operates a cloud-based genomic decision support platform called GenoACT, natively integrated into Electronic Health Record systems via SMART on FHIR standards. The platform processes saliva-collected genetic samples through a CLIA-certified, CAP-accredited laboratory, covering 600,000 genetic variants and 230+ carrier conditions, then automatically checks prescriptions against patient genetics for adverse reactions, efficacy, and dosing, while surfacing actionable hereditary risks within the clinician's existing EHR workflow. An evidence-based KnowledgeBase — curated by clinicians, geneticists, genetic counselors, and clinical pharmacists and continuously updated as new research emerges — powers the underlying clinical logic.

ActX generates revenue through multiple streams: direct-to-patient genetic testing paid out-of-pocket (with HSA/FSA eligibility, not insurance-covered), a $95 medical interpretation service for existing 23andMe customers, quote-based enterprise subscription licensing to health systems and physician practices, and laboratory reporting services sold to other clinical laboratories. Distribution is hybrid, combining direct enterprise field sales, EHR partner marketplaces (Epic App Orchard, athenahealth Marketplace, Oracle Cloud Marketplace, Greenway Marketplace, etc.), and direct-to-consumer sign-up with physician authorization. The company has accumulated 15+ named health system customers including NorthShore, Yale New Haven Health, Baptist Health, Nemours, Cone Health, Mount Sinai, Vancouver Clinic, Lakeland Regional Health, Nicklaus Children's, UAB Medicine, Ochsner, and St. Elizabeth, with integrations spanning 10+ major EHR platforms and an addressable footprint of 75,000+ providers via athenahealth and 100+ EHR systems via NewCrop.

The company is venture-backed only at the angel/early-stage scale (Alliance of Angels, Keiretsu Forum/Capital, Puget Sound Venture Club), with approximately $6.1 million total disclosed funding raised through a December 2022 SEC Form D filing, and an 11-50 employee headcount. It holds CAP laboratory accreditation (passed 2024 inspection with zero deficiencies), CLIA certification, HIPAA compliance, and TX-RAMP Level 2 certification, and has extended multi-year enterprise commitments (e.g., Baptist Health through 2028) and entered a CMS-funded dementia care program (GUIDE Initiative) in 2026.

ActX firmographics

Firmographics
Name
ActX
Legal name
ActX, Inc.
Website
https://actx.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
ActX, founded in 2012, provides EHR-integrated genomic decision support through its GenoACT platform. The system automatically checks prescriptions against patient genetics and identifies actionable hereditary risks for health systems, practices, and patients across 10+ major EHR platforms.
Ownership category
akta.pro rank

ActX industry classification

Industry
Product category
Clinical Genomics Software
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Genomic decision support
  • Pharmacogenomics platform
  • Precision medicine software
  • EHR-integrated genomics
  • Clinical decision support

Where ActX is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ActX business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Direct Patient Genetic Testing: Patients pay directly for the ActX service after physician authorization. Service includes pharmacogenomics, hereditary risk assessment, and carrier status screening. Currently not covered by insurance. HSA/FSA funds accepted.
  2. 23andMe Analysis Service: Interpretation service for 23andMe raw genetic data. Patients pay $95 for ActX analysis that provides more extensive coverage on medications, risks, and carrier conditions than standard 23andMe reports.
  3. Health System Enterprise Licensing: Health systems pay for enterprise-wide genomic decision support deployment. Includes EHR integration, provider access, and system-wide analytics. Implementation in weeks rather than years.
  4. Laboratory Reporting Services: Pharmacogenomic reporting services for other laboratories. Includes PDF PGX reports with customizable panels, CAP accredited genomic interpretation, and provider/patient portal options.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-go23andMe Analysis - One-time interpretation service
One time/ perpetual licensePay-as-you-goFull Service - Complete genomic screening
One time/ perpetual licensePay-as-you-goPharmacogenomics Service - Medication-focused only
SubscriptionAnnualEnterprise Health System Deployment

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

ActX product offering

Product offering

Core offering

ActX builds and operates GenoACT, an EHR-integrated genomic decision support platform that automatically checks prescriptions against patient genetics for drug-genome interactions, adverse reactions, efficacy, and dosing, while alerting physicians to actionable hereditary risks and carrier status. The company processes patient saliva samples through its CLIA-certified laboratory using micro-array testing covering 600,000 genetic variants, with continuously updated clinical interpretation delivered in real time inside the physician's existing EHR workflow.

Product overview

ActX offers a unified genomic decision support platform called GenoACT that provides precision medicine capabilities integrated into Electronic Health Records. The core product portfolio includes the GenoACT Genomic Decision Support platform, ActX Full Service (comprehensive pharmacogenomics, hereditary risks, carrier status), and ActX Pharmacogenomic Service (drug-genome interactions only). Supporting modules include a patient mobile app (My ActX Genomic Profile), Analytics Dashboard for population health insights, Laboratory Reporting services, Medications by Class visualization, Patient Genetic Testing Recommendations, Dosage and Route-Aware Clinical Alerting, and a Traits feature for non-medical genetic information. ActX also offers a 23andMe integration service for interpreting raw genetic data. The platform integrates with 10 major EHR systems including Epic, Oracle Health, Veradigm, and others via SMART on FHIR standards.

Differentiator

Problem solved

Functional benefit

Brands

  • GenoACT: ActX's Genetic Clinical Decision Support Service that provides actionable genomic decision support within EHR workflow
  • Actionable Genomics
  • Genomic Decision Support

Products and services

  • GenoACT Genomic Decision Support Core genomic decision support platform integrated into major EHR systems (Epic, Oracle Health, athenahealth, eClinicalWorks, Greenway, NextGen, Veradigm, Aprima, CompuGroup Medical, NewCrop) that automatically checks prescriptions against patient genetics for drug-genome interactions, adverse reactions, efficacy, and dosing, while alerting physicians to actionable hereditary risks and carrier status. Targeted at health systems, hospitals, and physician practices.
  • ActX Full Service Comprehensive genomic screening service for individual patients covering pharmacogenomics (drug-genome interactions), hereditary risk assessment for actionable conditions, and carrier status screening for 230+ genetic diseases. Patients pay directly after physician authorization, with HSA/FSA eligibility.
  • ActX Pharmacogenomic Service (PGx-only) Focused service providing only drug-genome interaction information and medication-related risks for patients who prefer not to receive non-medication hereditary risk information. Upgradeable to Full Service for a small fee.
  • My ActX Genomic Profile Mobile App Free mobile application available on iOS and Android that allows patients to access their ActX Genomic Profile, check medications via Med Check functionality, view hereditary risks, and share results with healthcare providers.
  • ActX Laboratory Reporting Service Pharmacogenomic reporting and interpretation service for clinical laboratories, offering PDF PGX reports with customizable panels, discrete genetic data file transmission (CSV/VCF), optional provider/patient portals, CAP-accredited genomic interpretation, and EHR integration capabilities for the lab's customers.
  • ActX for 23andMe Medical genetic interpretation service for existing 23andMe customers, providing $95 analysis of raw 23andMe genetic data with more extensive coverage on medications, hereditary risks, and carrier conditions than standard 23andMe Health + Ancestry reports. The interpretation integrates into the patient's medical chart for physician use.

Quantifiable outcome

  • 89-99% of patients carry variants affecting medications
  • +4 more outcomes

Companies that use ActX

Customer profile

Named customers14 records

Segments6 records

Ideal customer profiles5 records

ActX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability3 records

Feature7 records

ActX partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered secondary, core and strategic.

  • AprimasecondaryTechnology or Integration · 11 April 2017Aprima Medical Software integration partnership to bring precision medicine into the physician's office. ActX provides genomic decision support integrated with Aprima EHR.
  • CompuGroup Medical (CGM)coreTechnology or Integration · 4 January 2017ActX partnered with CompuGroup Medical US to integrate real-time genomic decision support into CGM's EHR solutions (CGM webEHR and CGM CLINICAL). CGM Genomics powered by ActX branding. Provides prescription checking and actionable risk alerts within CGM EHR workflow.
  • athenahealthcoreTechnology or Integration · 13 October 2016ActX partnered through athenahealth's 'More Disruption Please' (MDP) program, making ActX part of the athenahealth Marketplace offerings. Links athenaClinicals with ActX capabilities to incorporate genomic decision support into existing physician workflow. Access to athenahealth's network of 75,000+ healthcare providers.
  • Greenway HealthsecondaryTechnology or Integration · 15 October 2014ActX joined Greenway Health online Marketplace as approved partner for PrimeSUITE EHR users. Certified Greenway Marketplace partner. Integration checks prescriptions against patient genetics within Greenway electronic chart.
  • EpiccoreTechnology or IntegrationActX provides genomic decision support integrated into EpicCare EHR. Available through Epic App Orchard marketplace. ActX is integrated into Order Entry and Genomic tab, checking medications and alerting for actionable risks. Featured Epic customers include NorthShore, Yale New Haven Health, Baptist Health, and others. Epic President Carl Dvorak publicly endorsed ActX's integration capabilities.
  • Oracle Health (Cerner)coreTechnology or IntegrationActX offers genomic decision support platform built for Oracle Health (Cerner EHR). Available as SMART on FHIR app through Oracle Cloud Marketplace. ActX is a validated Cerner Code developer partner. Provides real-time decision support, alerts for actionable genomic risks, integrated patient Genomic Profile, and customizable content.
  • eClinicalWorkssecondaryTechnology or IntegrationActX integrated with eClinicalWorks EHR to bring precision medicine to patient care. Turn-key approach focusing on Actionable Genomics checking prescriptions for adverse reactions, efficacy, and dosing. Genomic Profiles accessible within eClinicalWorks patient chart.
  • NextGen HealthcaresecondaryTechnology or IntegrationActX partnered with NextGen to make genomic decision support available within NextGen EHR workflow. Identifies actionable hereditary risks and alerts clinicians in their inbox for 3-4% of patients with actionable risks.
  • NewCropcoreTechnology or IntegrationActX partnered with NewCrop prescribing system and associated EHR partners. Integration means providers using 100+ partner EHR systems can see genetically-based alerts about medication efficacy, dosing, and adverse reactions. Access through NewCrop's extensive partner network.
  • Veradigm (Allscripts)secondaryTechnology or IntegrationActX integrated with Veradigm EHR (formerly Allscripts) and Alterra TouchWorks. Brings Actionable Genomics into practices integrated into the electronic chart. Checks prescriptions and alerts for adverse effects, efficacy, dosing issues.
  • NavRxstrategicStrategic or Co-development PartnerCollaboration between ActX and NavRx for the GUIDE Dementia Care Initiative. ActX provides dynamic pharmacogenomics reporting for thousands of early dementia patients. Project incorporates pharmacogenomics and metabolomics for medication management, enabled by clinical pharmacists.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

ActX competitors and assessment

Company assessment

Direct peers

  • Genomind: Pharmacogenomics testing and clinical decision support company offering GeneSight, a PGx panel integrated into mental-health prescribing workflows. Directly comparable to ActX as a PGx-CDS provider targeting clinicians for medication optimization.
  • YouScript (by Streamline Health): Pharmacogenomics decision support platform providing drug-gene interaction alerts for prescribers, with EHR integration. Closely aligned with ActX's GenoACT value proposition of real-time PGx guidance within the prescribing workflow.
  • Translational Software: PGx knowledge base and clinical decision support vendor that delivers pharmacogenomic interpretation to health systems and labs via APIs and EHR integrations. Comparable to ActX as a content + integration PGx-CDS competitor.
  • 2bPrecise (an Allscripts/Veradigm-affiliated platform): Genomics clinical decision support platform originally built inside Allscripts, delivering precision-medicine insights inside the EHR. Direct functional competitor to ActX, particularly in the Veradigm/Allscripts ecosystem.
  • Molecular Health: Clinical genomics decision support company providing treatment-guidance analytics based on molecular and genetic data. Comparable to ActX as an enterprise clinical genomics decision-support vendor for health systems.
  • Coriell Life Sciences: Pharmacogenomics and precision medicine company offering enterprise PGx decision support for health systems and employee benefits. Comparable to ActX in serving large populations with PGx-CDS offerings.

Broad incumbents

  • SOPHiA Genetics: Genomics analytics platform for hospitals and labs offering AI-driven interpretation across multiple testing areas. Broader-scope incumbent with overlapping clinical-decision-support capabilities for genomics, though more lab-oriented than EHR-prescribing-focused.
  • Myriad Genetics: Large established genetics testing company with pharmacogenomics (GeneSight) and hereditary risk products. Broader incumbent offering overlap with ActX's PGx and hereditary-risk service lines, though via lab testing rather than primarily EHR-native CDS.
  • Epic (Genomics Module / Cosmos): Dominant EHR vendor whose platform is the primary distribution channel for ActX. Represents both the largest go-to-market opportunity and the principal incumbent risk if Epic ships native genomics decision support to compete directly.

Others

  • 23andMe: Consumer genetic testing company whose raw-data files are interpreted by ActX's $95 service. Adjacent partner rather than direct competitor — ActX monetizes 23andMe's installed base by providing medical-grade interpretation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

ActX social profiles

Digital presence

ActX compliance and trust

Trust signal

Compliance4 records

ActX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ActX leadership team

Management profile

Number of profiles

Profiles3 records

ActX funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ActX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ActX

What does ActX do?

ActX builds and operates GenoACT, an EHR-integrated genomic decision support platform that automatically checks prescriptions against patient genetics for drug-genome interactions, adverse reactions, efficacy, and dosing, while alerting physicians to actionable hereditary risks and carrier status. The company processes patient saliva samples through its CLIA-certified laboratory using micro-array testing covering 600,000 genetic variants, with continuously updated clinical interpretation delivered in real time inside the physician's existing EHR workflow.

Is ActX a public or private company?

ActX is a private company. It is classified as venture growth investor backed and is currently operating.

When was ActX founded?

ActX was founded in 2012. It employs 11 to 50 people.

Where is ActX based?

ActX is headquartered in Seattle, United States, in the North America region.

How does ActX make money?

Four revenue lines are on record. Direct Patient Genetic Testing is the primary driver. The others are 23andMe Analysis Service, health System Enterprise Licensing and laboratory Reporting Services.

Who are ActX's main competitors?

Direct peers on record are Genomind, YouScript (by Streamline Health), Translational Software, 2bPrecise (an Allscripts/Veradigm-affiliated platform), Molecular Health and Coriell Life Sciences. Broad incumbents are SOPHiA Genetics, Myriad Genetics and Epic (Genomics Module / Cosmos). 23andMe is listed as an others.

Does ActX have an API?

No public API is recorded for ActX.

What industry is ActX in?

ActX's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLACAKAH, Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DActX, Inc. filed a Form D with the SEC to report an exempt offering of securities under Rule 506(b). The company raised a total of $5,993,148 from 43 investors, which includes the conversion of convertible notes valued at approximately $4.2 million.PrwebActX Adds COVID-19 Susceptibility Assessment to Genomic ScreeningActX announced the addition of a COVID-19 susceptibility assessment to its GenoACT genetic clinical decision support service. The new feature helps physicians interpret patient genetic data regarding infection risk, primarily based on blood type evidence. Patients are notified of these updates when viewing their results online.Healthcare IT NewsNorthShore makes genomic decision support available in Epic with help from ActXNorthShore Health integrated ActX's genomic decision support into its Epic EHR, enabling clinicians to check prescriptions against patient genomic profiles. The system has tested 10,000 patients, with 99.8% having actionable findings, and 99% of eligible physicians ordered tests.PrwebNorthShore provides real time genomic decision support to 10,000 patients using the ActX ServiceNorthShore University HealthSystem expanded its DNA-10K genomic testing program to 10,000 patients, integrating ActX's real-time decision support into Epic. The program achieved 99% physician ordering and 99.8% actionable findings. NorthShore aims to make pharmacogenomics standard care across its system.PrwebActX Launches a Genetic Medical Interpretation Service for 23andMe CustomersActX has launched a new service allowing 23andMe customers to access genetic medical interpretations through a smartphone application and web portal. The service analyzes raw genetic data to provide physicians with clinical decision support regarding drug-genome interactions and hereditary risks, utilizing CAP-accredited laboratory testing for accuracy. ActX ensures the privacy of this data in compliance with HIPAA guidelines while integrating results into electronic health records.PrwebYale New Haven Health System Implements ActX Genomic Decision Support Within EpicYale New Haven Health System is integrating ActX Genomic Decision Support into its Epic electronic health record, starting with pharmacogenomics. The system will alert prescribers to potential adverse reactions, drug efficacy, or dosing based on patient genetic profiles. Initial focus is on behavioral health, cardiology, infectious disease, and pediatrics.PR NewswireAprima Medical Software and ActX Partner to Deliver Integrated Genomic Decision Support SolutionAprima Medical Software and ActX announced a partnership to integrate the ActX Genomic Decision Support platform into Aprima's electronic health record system. This integration provides healthcare providers with real-time genomic insights to support personalized medication choices and screening based on patient genetic profiles. The combined solution is scheduled to become available to Aprima clients in late summer 2017.PR NewswireActX Partners with CompuGroup Medical US Introduces Built-in Precision Medicine Tools to Users of the Company's Electronic Health Record SolutionsActX has partnered with CompuGroup Medical US to integrate real-time genomic decision support tools into CGM's Electronic Health Record solutions, including CGM webEHR and CGM CLINICAL. The integration enables healthcare providers to receive genomics-based alerts about prescription efficacy, adverse reactions, and dosing issues based on patient genetic profiles. ActX CEO Andrew Ury and CGM US CEO Werner Rodorff expressed excitement about bringing precision medicine capabilities to CGM's physician customer base.PR NewswireActX Partners with athenahealth's 'More Disruption Please' Program to Bring Integrated Genomic Decision Support into Medical CareActX, a genomic decision support provider, announced a partnership with athenahealth's 'More Disruption Please' program on October 13, 2016, integrating its genomic decision support services into athenahealth's network of over 75,000 healthcare providers through athenaClinicals. The ActX service automatically checks prescriptions for potential adverse drug reactions, efficacy issues, and dosing problems based on patient genetics, as well as alerting physicians to serious non-medication genetic risks. This partnership allows ActX to expand its reach within athenahealth's ecosystem while providing precision medicine capabilities to a broader network of physicians.PR NewswireNorthShore University HealthSystem Implements ActX Genomic Decision Support Within EpicNorthShore University HealthSystem of Evanston, Illinois is implementing ActX Genomic Decision Support within Epic's electronic health record platform to integrate pharmacogenomics into routine clinical care. The system will enable real-time alerts to prescribers about potential adverse drug reactions, efficacy issues, or dosing recommendations based on each patient's genetic profile. The implementation aims to make genetic data accessible and actionable for NorthShore's 2,400 employed and affiliated physicians, representing a significant step toward personalized medicine at scale.